Mei-Shih Announces Board Approval to Cancel Fund Lending to Subsidiary Lotus International Pte. Ltd.
Mei-Shih Chemical Pharmaceutical Co., Ltd. has resolved at its board meeting to cancel a USD 20 mill… · 2026-06-26
美時 News Releases
Meiji Chemical & Pharmaceutical Announces Board Approval to Cancel Funding Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
Meiji Chemical & Pharmaceutical Co., Ltd. announced that its board has approved the cancellation of … · 2026-06-26
Meiji Group Announces Executive Appointment: Shen Ye as Financial Vice General Manager
Meiji Group has announced the appointment of Shen Ye as Financial Vice General Manager, effective Ju… · 2026-06-26
Mei-Shi Announces Implementation Status of Subsidiary's Plan to Rectify Excessive Lending to Third Parties
Alvogen Pharma US Inc., a 100% subsidiary of Mei-Shi, has completed its improvement plan regarding e… · 2026-06-26
Meiji Announces Board Approval for Capital Increase in Korean Subsidiary Alvogen Korea Holdings Ltd.
Meiji has announced that its board of directors has approved a capital increase in its 100%-owned Ko… · 2026-06-26
Mei-Shi Announces Board Approval for Capital Increase in Singapore Subsidiary Lotus International Pte. Ltd.
Mei-Shi has announced that its board of directors has approved a capital increase of USD 20 million … · 2026-06-26
Mei-Shi Subsidiary Lotus Pharma Bulgaria EOOD Announces Fund Lending to Parent Company
Lotus Pharma Bulgaria EOOD, a subsidiary of Mei-Shi, announced a new fund lending of USD 21 million … · 2026-06-18
MiShi Announces Key Resolutions from 115th Annual Shareholders Meeting
MiShi announced the passage of key resolutions at its 115th annual shareholders meeting held on June… · 2026-06-16
MiShi Announces Shareholders' Meeting Resolution to Lift Non-Compete Restrictions on Director
On June 16, 115, MiShi's annual shareholders' meeting resolved to lift non-compete restrictions on d… · 2026-06-16
Melaleuca Pharmaceutical Board Resolution to Issue First Overseas Unsecured Convertible Bonds
Melaleuca Pharmaceutical has resolved at its board meeting to issue its first overseas unsecured con… · 2026-06-11
[Lotus] Subsidiary Alvogen Korea Acquires Marketing Authorization for Product 'Matterhorn' in the Korean Market from OM PHARMA SA
Lotus Pharmaceutical (Taiwan) announced that its subsidiary, Alvogen Korea, has decided to acquire i… · 2026-05-21
[Lotus] Announcement regarding funds loan to Singapore subsidiary Lotus International Pte. Ltd.
On May 21, 2026, Lotus Pharmaceutical announced a $20 million USD (633 million TWD) loan to its subs… · 2026-05-21
Meiji (美時) Invited to Online Investor Seminar Hosted by Morgan Stanley
Meiji (美時) has accepted an invitation to an online investor seminar organized by Morgan Stanley. The… · 2026-05-15
Meiji (美時) Invited to Online Investor Seminar Hosted by Morgan Stanley
Meiji (美時) has accepted an invitation to an online investor seminar organized by Morgan Stanley. The… · 2026-05-15
【Lotus Pharmaceutical】Announcement of the Board of Directors' Resolution to Approve the 2026 First Quarter Financial Report
Lotus Pharmaceutical's Board of Directors has approved the financial report for the first quarter of… · 2026-05-11
【Lotus Pharmaceutical】Announcement of board resolution to approve capital increase in Singaporean subsidiary Lotus International Pte. Ltd.
Lotus Pharmaceutical's board of directors approved a capital increase in its Singaporean subsidiary,… · 2026-05-11
【Lotus Pharmaceutical】Announcement of the Board of Directors' Resolution to Approve the 2026 First Quarter Financial Report
Lotus Pharmaceutical's Board of Directors has approved the financial report for the first quarter of… · 2026-05-11
【Mei Shi】The Company Disposes of 100% Ownership of its Japanese Subsidiary Lotus Japan Holdings Co., Ltd.
Mei Shi Pharmaceutical announced the disposal of 100% ownership of its Japanese subsidiary, Lotus Ja… · 2026-05-11
【Lotus Pharmaceutical】Announcement of board resolution to approve capital increase in Singaporean subsidiary Lotus International Pte. Ltd.
Lotus Pharmaceutical's board of directors approved a capital increase in its Singaporean subsidiary,… · 2026-05-11
【Mei Shi】The Company Disposes of 100% Ownership of its Japanese Subsidiary Lotus Japan Holdings Co., Ltd.
Mei Shi Pharmaceutical announced the disposal of 100% ownership of its Japanese subsidiary, Lotus Ja… · 2026-05-11
[Lotus Pharmaceutical] May 2026 Revenue Reached NTD 2.32 Billion (+105.8% YoY)
Lotus Pharmaceutical announced its consolidated revenue for May 2026 reached NTD 2.32 billion (NTD 2… · 2026-05-01
Meiji Announces Board Meeting Date for Q1 2026 Consolidated Financial Report
Meiji announced that its board meeting to review the Q1 2026 consolidated financial report will be h… · 2026-04-30
Meiji Announces Board Meeting Date for Q1 2026 Consolidated Financial Report
Meiji announced that its board meeting to review the Q1 2026 consolidated financial report will be h… · 2026-04-30
Meiji Announces Board Meeting Date for Q1 2026 Consolidated Financial Report
Meiji announced that its board meeting to review the Q1 2026 consolidated financial report will be h… · 2026-04-30
MeiShi Announces Board Resolution to Convene 115th (2026) Annual General Meeting (Changed Meeting Location and Added Agenda Items)
MeiShi's board of directors resolved on April 16, 115 (2026) to hold the company's Annual General Me… · 2026-04-16
MeiShi Announces Board Resolution to Convene 115th (2026) Annual General Meeting (Changed Meeting Location and Added Agenda Items)
MeiShi's board of directors resolved on April 16, 115 (2026) to hold the company's Annual General Me… · 2026-04-16
PharmaEssentia: April 2026 Monthly Revenue NT$3.086 Billion (YoY +19.9%)
PharmaEssentia announced its monthly revenue for April 2026, reaching NT$3.086 billion. This represe… · 2026-04-01
PharmaEssentia: April 2026 Monthly Revenue NT$3.086 Billion (YoY +19.9%)
PharmaEssentia announced its monthly revenue for April 2026, reaching NT$3.086 billion. This represe… · 2026-04-01
Megalith (1795) Announces March 2026 Revenue of NT$4.354 Billion (Year-over-Year Increase of +173.6%)
Megalith (1795) reported its March 2026 revenue at NT$4.354 billion (NT$4,354,277 thousand), marking… · 2026-03-01
Megalith (1795) Announces March 2026 Revenue of NT$4.354 Billion (Year-over-Year Increase of +173.6%)
Megalith (1795) reported its March 2026 revenue at NT$4.354 billion (NT$4,354,277 thousand), marking… · 2026-03-01
[Amphastar] February 2026 Monthly Revenue NT$2.238 Billion (YoY +131.5%)
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring… · 2026-02-01
[Amphastar] February 2026 Monthly Revenue NT$2.238 Billion (YoY +131.5%)
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring… · 2026-02-01